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NADPH oxidase (NOX) is a multicomponent enzyme complex that generates reactive oxygen species (ROS) in response to a 
wide range of stimuli. ROS is involved as key secondary messengers in numerous signaling pathways, and NADPH oxidases 
complex has been increasingly recognized as key elements of intracellular signaling of hepatic fibrogenesis. In the liver, NADPH 
oxidase is functionally expressed both in the phagocytic form and in the non-phagocytic form. The non-phagocytic NADPH 
oxidase complex is structurally and functionally similar to the phagocytic NADPH, resulting in reduction of molecular oxygen to 
generate superoxide. There are six homologous NOX proteins in the non-phagocytic forms of NADPH oxidase. An emerging 
concept is that both phagocytic and nonphagocytic NADPH oxidase components in hepatic stellate cells (HSCs) mediate hepatic 
fibrosis, suggesting its potential role as a pharmacological target for anti-fibrotic therapy. The molecular components and 
signaling pathways of various NADPH oxidase homologues that are critical for the fibrotic activity in HSCs need to be more 
clearly identified. (Korean J Hepatol 2011;17:251-257)
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INTRODUCTION
Chronic hepatic inflammation which is caused by excessive 
alcoholic consumption, hepatitis B or C virus, and non-alcoholic 
steatohepatitis results in hepatic fibrosis.
1 The terminal 
outcome of liver fibrosis is liver cirrhosis, characterized by 
excessive deposition of extracellular matrix proteins and the 
appearance of regenerative nodules, accompanied by hepatic 
failure, portal hypertention and hepatocellular carcinoma. 
Portal hypertension may cause serious complications such 
as esophageal variceal bleeding, ascites, and hepatic 
encephalopathy that are the major causes of death in cirrhotic 
patients. However, there is no effective anti-fibrotic therapy 
to treat or reverse hepatic fibrosis and liver cirrhosis. 
Therefore there is an urgent need to develop anti-fibrotic 
agent through the research for the molecular pathogenesis of 
hepatic fibrogenesis. 
The hepatic stellate cell (HSC) is the main fibrogenic cell 
type in the injured liver and it also has been identified as an 
important effector in liver inflammation.
1 HSCs are located 
in the space of Disse in close proximity to hepatocytes on 
one side and endothelial and Kupffer cells on the other side. 
Quiescent HSCs are desmin-positive, perisinusoidal cells 
that are the primary cell in the body responsible for vitamin 
A storage.
1 Upon activation by liver injury, quiescent HSCs 
transdifferentiate into myofibroblast which produce inflam-
matory cytokines and several extracellular matrix proteins 
and glycoproteins including at least five collagen types, 
fibronectin, laminin, entactin, tenascin, and several proteo-
glycans.
2 
Reactive oxygen species (ROS) are involved as key 
secondary messengers in numerous signaling pathways including 252  The Korean Journal of Hepatology Vol. 17. No. 4, December 2011
Table 1. The components of NADPH oxidase homologues
Classification Membrane bound components Cytoplasmic components
NOX2 NOX2, P22
phox p40
phox, p47
phox, P67
phox, Rac
NOX1 NOX1, p22
phox p40
phox, p47
phox  or NOXO1, P67
phox or NOXA1, Rac
NOX3 NOX3, p22
phox p40
phox, NOXO1, NOXA1, Rac
NOX4 NOX4, p22
phox
NOX, NADPH oxidase; NOXO, NADPH oxidase organizer; NOXA, NADPH oxidase activator; Rac, Ras-related C3 botulinum toxin 
substrate.
transcriptional regulation, differentiation, proliferation to 
oncogenic transformation, and activation of programmed 
cell death.
3 It has previously been demonstrated that ROS 
significantly contributes hepatic fibrogenesis from various 
liver injuries including alcohol abuse, hepatitis C virus 
infection, iron overload and chronic cholestasis.
4,5 ROS can 
stimulate the production of the type I collagen,
6 and may act 
as an intracellular signaling mediator of the fibrogenic 
action of TGF-β.
7,8 ROS may be generated by multiple 
sources including mitochondrial respiratory chain, cytochrome 
p4502E1, peroxisomes, and NADPH oxidases (NOXs) in 
the liver.
5 Cumulating evidences indicate the critical role of 
NOX-mediated ROS in hepatic fibrogenesis which will be 
described in this review.
NADPH oxidase homologues and components
NOX is a multicomponent enzyme complex that generates 
ROS in response to a wide range of stimuli including TNF-α, 
IL-1β, leptin and angiotensin II (Ang II).
9,10 NOX generates 
superoxide (O2
․-) from molecular oxygen using NADPH as 
an electron donor, and superoxide converts to hydrogen 
peroxide (H2O2) by superoxide dismutase (SOD). Classic 
NOX is the phagocytic NOX found in neutrophils. The 
phagocytic NOX complex consists of the catalytic subunit  
gp91
phox (renamed NOX2) together with the regulatory subunit 
p22
phox  located in the membrane. The other regulatory 
components p47
phox, p40
phox, p67
phox and the small GTPase 
Rac are normally located in the cytoplasm.
11 Upon stimulation 
with agonists, the cytosolic subunits translocate to the 
membrane-bound cytochrome complex leading to enzymatic 
activity. Humans have 4 additional homologous NOX 
proteins (NOX1, NOX3, NOX4, NOX5) and 2 related enzymes 
(DUOX1, DUOX2) that may function in non-phagocytes.
11 
Among the seven members of the NOX family, NOX1 is 
structurally and functionally similar to NOX2. While NOX1 
is also p22
phox-dependent, NOX1 may use NOXO1 (homologue 
of p47
phox) to organize the enzyme assembly and NOXA1 
(homologue of p67
phox) for enzyme activation.
12 In contrast, 
NOX4 requires only p22
phox without recruitment of cytosolic 
regulatory components to exert its enzymatic activity.
13 
All NOX enzymes are able to catalyze the reduction of 
molecular oxygen to superoxide, but there are key differences 
in their activation, subunit composition, localization, and 
expression (Table 1, Fig. 1).
14
NADPH oxidase-mediated ROS generation and 
human diseases
Chronic granulomatous disease (CGD) has been described 
for several decades as a human disease resulting from 
defects in NOX complex.
15 The genetic defect of phagocytic 
NOX activity results in an inability to produce the superoxide 
anion necessary for killing bacteria and fungi by neutophils 
and phagocytes. The patients with CGD predispose to serious 
bacterial and fungal infections as well as granulomatous 
complications. It has been reported that at least 5 different 
genes involved in NOX activity may cause CGD.
15 The gene 
mutation of NOX2 on the X chromosome account for about 
two thirds of the cases and present as severe form with 
earlier symptom manifestation. Meanwhile, mutations in 
p47
phox, p67
phox, and p22
phox account for about one thirds of 
the cases as less severe form characterized by autosomal 
recessive inheritance.
16 
In contrast with CGD that are defective in NOX function, 
several human diseases are associated with excessive ROS 
production by an overactive NOX. NOX mediated oxidative 
stress may cause endothelial dysfunction, vascular smooth 
muscle contraction and hypertrophy that results in various 
vascular diseases such as hypertension, hypercholesterolemia, Yong-Han Paik, et al. NADPH oxidase and liver fibrosis  253
Figure 1. Structure of phagocytic NOX2 and non-phagocytic NOX1 complex. NOX, NADPH oxidase; NOXO, NADPH oxidase 
organizer; NOXA, NADPH oxidase activator; Rac, Ras-related C3 botulinum toxin substrate. 
and atherosclerosis.
14 Amyotrophic lateral sclerosis (ALS) 
is a progressive motor neuron degenerative disease. Although 
multiple factors seem to be implicated in the underlying 
pathogenesis, recent evidence strongly suggest that oxidative 
stress is an important component of disease progression of 
ALS.
17 It was reported that oxidative damage is increased in 
both sporadic and familial form of ALS which is associated 
with mutations of SOD1.
18 In a SOD1
G93A transgenic 
mouse, an animal model of ALS, both NOX1 and NOX2 are 
involved in disease progression.
19,20 In ALS pathogenesis, 
the activation of proinflammatory transcription factor NF-κB 
by TNF-α and IL-1β has been reported to involve NOX.
17 
More recently, the important role of neuronal inflammation 
associated with redox-active signaling endosomes (redoxosomes) 
has been reported.
21 After TNF-α or IL-1β stimulation, 
dynamin-dependent co-endocytosis of the ligand-activated 
receptor and NOX complexes occur.
22,23  As a next step, 
SOD1 is recruited to the redoxosome, where it binds to 
Rac1 and stabilizes the GTP-bound active form of Rac1.
22 
Oxidation of Rac1 by H2O2 uncouples SOD1 binding in a 
reversible fashion. The expression of ALS mutant forms of 
SOD1 (G93A) enhances NOX dependent superoxide production 
and Rac1 activation in redoxosome.
24  Taken together, 
mutations in SOD1 leads to increased NOX dependent ROS 
production and hyperactivation of proinflamamtory signaling 
that can kill motor neurons to develop ALS, where endosomal 
NOX regulation by SOD1/Rac1 interaction seems to be 
critical.
17 The possible disturbance of the above self-regulated 
redox signaling for NOX-derived ROS production may also 
be implicated in hepatic fibrogenesis. However, the detailed 
intracellular signaling of NOX-mediated superoxide production 
and subsequent conversion to H2O2 in HSCs is largely 
unknown.
Angiotensin II induces hepatic fibrosis via 
NADPH oxidase activation in hepatic stellate cells
Key elements of the renin angiotensin system such as 
angiotensin converting enzyme and angiotensin type I 
receptor (AT1R) are present in normal liver tissue, and there 
is major up-regulation of the system in the bile duct-ligated 
liver.
25 Several studies demonstrated that inhibition of 
Angiotensin II (Ang II) synthesis and/or the blockade of 
AT1R markedly decrease inﬂammation and hepatic ﬁrosis 
in experimental models of chronic liver injury.
26-28 In 
parallel, the study investigating the fibrogenic response in 
WT and AT1R
-/- mouse demonstrated that hepatic collagen 
accumulation was lower in AT1R
-/- mice compared to WT 
mice after bile duct ligation (BDL).
29 p47
phox-/- mice have 
been widely used as a genetic model to study NOX 
inhibition.
30-32 Bataller et al. demonstrated that p47
phox-/- 
mice showed attenuated liver injury and fibrosis compared 
with WT counterparts after BDL.
33 
As shown previously in the kidney,
34 Ang II exerts its 
activity for the regulation of intracellular pathways using 
NOX as a mediator in HSCs.
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demonstrate that Ang II is able to induce ROS production in 
human activated HSCs. Ang II induces a marked increase 
in ROS formation in dichlorodihydroﬂorescein diacetate 
(DCFDA)-loaded activated human HSCs. Ang II-induced 
ROS formation in HSCs is inhibited when HSCs are treated 
with either a NOX inhibitor diphenylene iodonium (DPI)
36 
or with the AT1R antagonist, losartan.
28 Furthermore, Ang 
II induces the phosphorylation of p47
phox through AT1R in 
activated HSCs. In particular, Ang II leads to an increase of 
intracellular ROS in HSCs isolated from wild type (WT) 
mice, but not in p47
phox-/- HSCs. Also, Ang II induces DNA 
synthesis and cell migration in WT HSCs, as well as 
phosphorylation of ERK and c-Jun, while these effects are 
blunted in p47
phox -/- HSCs.
33 Taken together, Ang II directly 
acts on HSCs through the activation of the NOX complex 
and the subsequent production of ROS. In addition, NOX is 
a crucial mediator of the proliferative action of PDGF and 
profibrogenic action of leptin.
37,38 Leptin-induced NOX acts 
downstream of JAK activation but is independent of 
STAT3.
38 These reports in conjunction with previous studies 
on Ang II, place NOX in the center of the fibrogenic signaling 
response in HSCs and demonstrate its potential pharma-
cological target for antifibrotic therapies.
The molecular mechanism of NOX activation by Ang II is 
still incompletely understood. In vascular smooth muscle 
cell, Ang II-stimulated ROS generation is biphasic.
39 The 
fast response is dependent on protein kinase C (PKC) which 
phosphorylates p47
phox then phosphorylated p47
phox translo-
cates to membrane where it activates NOX catalytic subunit 
NOX1 and/or NOX2. The slow response requires Rac acti-
vation by upstream c-Src, EGF receptor transactivation, 
phosphatidylinositol-3-kinase activation.
39 Ang II may 
stimulate PKC-dependent NOX activity through three 
different phospholipases (PL) such as PLC, PLD, and PLA2.
14 
The prolonged production of NOX-mediated ROS requires 
upregulation of NOX catalytic subunits and components.
40
Both phagocytic and non-phagocytic NADPH 
oxidases in hepatic stellate cells mediate 
hepatic  ﬁrosis
In the liver, NOX is functionally expressed both in the 
phagocytic form and in the non-phagocytic form.
41 Through 
analysis of mRNA expression of NOX components in 
isolated liver cell tractions from wild type C57BL/6 mice, 
we demonstrated that phagocytic NOX components such as 
NOX2, p40
phox, p47
phox, and p67
phox are mainly expressed in 
Kupffer cells, whereas nonphagocytic NOX components 
including NOX1, NOXO1, and NOXA1 are expressed in 
HSCs and endothelial cells.
42
Although NOX plays an important role in HSCs activation, 
the exact structure of this complex is still unknown. All 
components and functionalities of the phagocytic NOX 
are already well established, but the respective interactions 
between the non-phagocytic NOX components are still under 
investigation. p47
phox is well established component as 
playing a central role in the activity of NOX in HSC.
33 
Another integral component required for the activation of 
NOX is Rac1. Rac1 is a member of the Rho family of small 
GTPase proteins that regulates cell proliferation and 
dynamic reorganization of the actin cytoskeleton.
43
We reported that both NOX1 and NOX2 proteins are 
upregulated in the fibrotic liver. In particular, non-phagocytic 
NOX components as well as phagocytic NOX are upregulated 
in activated HSCs compared to quiescent HSCs.
42 Wild-type 
HSCs express the mRNAs for both phagocytic NOX2 and 
non-phagocytic NOX including NOX1 and NOX4. HSCs 
also express other NOX components including p47
phox, 
p67
phox, p40
phox, NOXO1, NOXA1, and Rac1. Both phagocytic 
and non-phagocytic NOX catalytic subunits including 
NOX1, NOX2, and NOX4 are upregulated in activated 
HSCs compared to quiescent HSCs. Indeed, the mRNA for 
the cytoplasmic factor p47
phox and the cell membrane 
proteins NOX2 and NOX1 are detected at very low levels in 
quiescent HSCs by real time RT-PCR, while they are highly 
expressed following HSC activation in culture and in cells 
freshly isolated from patients with liver ﬁrosis.
33,42 These 
data indicate that after HSCs are activated in vivo, there is 
activation of both phagocytic and non-phagocytic NOX 
components.
Regarding the contributory role of phagocytic NOX2 and 
non-phagocytic NOX1 in hepatic fibrosis, we observed 
that mice deficient for either NOX1 or NOX2 displayed 
significantly less hepatic fibrosis compared to WT mice 
after CCl4 injections or BDL.
42 Through experiments of 
hepatic fibrosis induction in NOX1 or NOX2 bone marrow 
chimeric mice, we demonstrated that both NOX1 and NOX2 
in endogenous liver cells including HSCs mediate hepatic 
fibrosis.
42 Recently other investigator also reported that 
NOX1 mediates hepatic fibrosis by mechanism that Yong-Han Paik, et al. NADPH oxidase and liver fibrosis  255
Figure 2. Profibrogenic role of NADPH oxidase-derived ROS in 
hepatic stellate cells. Ang II, angiotensin II; PDGF, platelet 
derived growth factor; AT1R; angiotensin type 1 receptor; ObR, 
leptin receptor; PDGFR, PDGF receptor; NOX, NADPH 
oxidase; ROS, reactive oxygen species; TGF, transforming 
growth factor; MAPK, mitogen activated protein kinase; PI3K, 
phosphatidylinositol 3-kinase; PTEN, phosphatase and tensin 
homologue; ERK, extracellular signal-regulated kinase; JNK, 
c-Jun N-terminal kinase; Akt, protein kinase B.
NOX1-derived ROS oxidize and inactivate phosphatase and 
tensin homologue (PTEN) resulting in protein kinase B 
(Akt)/forkhead box O(FOXO) 4 activation and promoting 
HSC proliferation.
44 Thus, non-phagocytic NOX as well as 
phagocytic NOX represents a fundamental mediator in 
experimental liver ﬁbrosis.
In addition to receptor-mediated agonists such as Ang II, 
NOX may be activated in HSCs by the engulfment of apoptotic 
bodies from dying hepatocytes leading to the up-regulation 
of collagen α1(I) in HSCs.
45 The engulfment of apoptotic 
bodies not only acts on macrophages stimulating production 
of TGFβ1,
46 but also on HSCs promoting their activation. In 
support of this model, apoptotic bodies activate NOX in 
HSCs, thereby up-regulating HSCs activation and ﬁrosis.
47 
Speciﬁcally, apoptotic bodies in HSCs increase ROS 
production in an NOX-dependent manner. The increased 
production of ROS and collagen in response to apoptotic 
bodies is blocked by DPI, a NOX inhibitor. Jiang et al. 
reported that phagocytosis of apoptotic hepatocytes directly 
induce HSC activation and collagen production via NOX2.
48 
It can be presumed that NOX2 expression in HSCs may 
reflect the phagocytic function of HSCs.
47 These results are 
again consistent with an important role of NOX in HSCs 
activation. The profibrogenic role of NOX-mediated ROS in 
HSCs is schematically summarized in Figure 2.
CONCLUSION
ROS has diverse effects with respect to different kinds, 
concentration, and cell types. Although higher concentration 
of ROS can be cytotoxic, lower concentration of ROS serves 
as second messengers during cellular responses to a variety 
of physiologic stimuli. Emerging evidences suggest that 
non-phagocytic NOX as well as phagocytic NOX in hepatic 
stellate cells mediate hepatic fibrosis. Because NOX2 
activity is important in host defense, targeting specific 
components of non-phagocytic NOX could be a reasonable 
approach to develop antifibrotic therapies that would not 
suppress NOX2-mediated host defences. The molecular 
mechanism of redox signaling associated with various NOX 
homologues in hepatic fibrogenesis is still largely unknown. 
A better understanding of contributory role of various NOX 
homologues in the development of hepatic fibrosis may 
enable to develop novel therapeutic to prevent or treat 
hepatic fibrosis.
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